The Incidentally Discovered Adrenal Mass

William F. Young, Jr., M.D.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author’s clinical recommendations.

A 68-year-old woman is incidentally found to have a left adrenal mass, 2.8 cm in diameter, on abdominal computed tomography that was ordered to evaluate right lower abdominal discomfort (which has since resolved). Her medical history is notable only for hypertension that has been well controlled with hydrochlorothiazide, at a dose of 25 mg daily. She reports no sweating, palpitations, headache, weight gain, or proximal muscle weakness. Her physical examination is unremarkable. How should she be evaluated?

The Clinical Problem

An adrenal “incidentaloma” is an adrenal mass, generally 1 cm or more in diameter, that is discovered serendipitously during a radiologic examination performed for indications other than an evaluation for adrenal disease. This definition excludes cases in which a symptomatic adrenal-dependent syndrome is “missed” because of a superficial interview or physical examination. The widespread use of abdominal ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) has resulted in the clinical dilemma of the adrenal incidentaloma.

Numerous autopsy studies have examined the frequency of incidental adrenal nodules. In a report on 25 studies, the overall frequency of adrenal adenomas in 87,065 autopsies was 6% (range, 1 to 32). Abdominal CT yields similar findings; a recent study reported a prevalence of adrenal incidentaloma of 4%. The prevalence of adrenal adenomas increases with increasing age: the probability of finding an unsuspected adrenal adenoma on abdominal CT in a patient between 20 and 29 years of age would be approximately 0.2%, as compared with approximately 7% in a patient over 70 years of age.

The majority of adrenal incidentalomas are clinically nonhypersecreting, benign adrenocortical adenomas. Other frequently reported diagnoses include cortisol-secreting adrenocortical adenoma, pheochromocytoma, adrenocortical carcinoma, and metastatic carcinoma.

Strategies and Evidence

The optimal diagnostic approach to a patient who has an adrenal incidentaloma has not been established. However, it is reasonable to start by taking a careful history and performing a physical examination, focusing on the signs and symptoms suggestive of adrenal hyperfunction or malignant disease (Table 1) and hormonal testing (Table 2). Although no specific diagnostic approach has been prospectively validated, an algorithm based on clinical experience and data regarding laboratory and imaging studies is shown in Figure 1.
In a report summarizing the results of 13 studies including 2005 patients with adrenal incidentalomas, autonomous cortisol secretion (independent of normal hypothalamic–pituitary control) was found in 5.3% of the patients. Since such patients do not have clinical Cushing’s syndrome and may have normal 24-hour urinary cortisol excretion, a measure of autonomous adrenocortical secretion is the best strategy for testing. Because there is no reliable way to distinguish between low-normal values and suppressed values with most commercially available corticotropin assays, adrenal autonomy is best assessed by an overnight dexamethasone (1 mg) suppression test (Table 2). Although the optimal cutoff value is debated, the use of a cortisol level greater than 5 μg per deciliter (138 nmol per liter) is standard to define abnormal values according to this test, because this level is considered to be a reasonable criterion for clinically significant glucocorticoid secretory autonomy. The specificity of the 1-mg overnight dexamethasone suppression test is 91% ; if the result is abnormal, confirmatory testing should be performed to rule out a false positive result (Table 2).

Data from randomized trials are lacking to guide the optimal management of subclinical Cushing’s syndrome. A reasonable strategy is to consider adrenalectomy for younger patients (below the age of 40 years) and those with disorders that are potentially attributable to autonomous glucocorticoid secretion (e.g., the recent onset or worsening of underlying hypertension, diabetes mellitus, obesity, or osteoporosis). A patient with subclinical Cushing’s syndrome should receive glucocorticoid therapy perioperatively because of the risks of adrenal insufficiency, hemodynamic crisis, and death. The need for longer-term replacement and slow tapering of exogenous glucocorticoids should be assessed postoperatively. In limited case series, weight loss, improvement in hypertension or glycemic control or both, and the normalization of markers of bone turnover were reported after unilateral adrenalectomy in patients with subclinical Cushing’s syndrome.

### Hormonal Evaluation

#### Subclinical Cushing’s Syndrome

The term “subclinical” Cushing’s syndrome is used to refer to autonomous cortisol secretion in patients who do not have the typical signs and symptoms of hypercortisolism. Although the obvious stigmata of Cushing’s syndrome are absent, these patients may have the adverse effects of continuous, endogenous cortisol secretion, including hypertension, obesity, diabetes mellitus, and osteoporosis.

In a report summarizing the results of 13 studies including 2005 patients with adrenal incidentalomas, autonomous cortisol secretion (independent of normal hypothalamic–pituitary control) was found in 5.3% of the patients. Since such patients do not have clinical Cushing’s syndrome and may have normal 24-hour urinary cortisol excretion, a measure of autonomous adrenocortical secretion is the best strategy for testing. Because there is no reliable way to distinguish between low-normal values and suppressed values with most commercially available corticotropin assays, adrenal autonomy is best assessed by an overnight dexamethasone (1 mg) suppression test (Table 2). Although the optimal cutoff value is debated, the use of a cortisol level greater than 5 μg per deciliter (138 nmol per liter) is standard to define abnormal values according to this test, because this level is considered to be a reasonable criterion for clinically significant glucocorticoid secretory autonomy. The specificity of the 1-mg overnight dexamethasone suppression test is 91% ; if the result is abnormal, confirmatory testing should be performed to rule out a false positive result (Table 2).

Data from randomized trials are lacking to guide the optimal management of subclinical Cushing’s syndrome. A reasonable strategy is to consider adrenalectomy for younger patients (below the age of 40 years) and those with disorders that are potentially attributable to autonomous glucocorticoid secretion (e.g., the recent onset or worsening of underlying hypertension, diabetes mellitus, obesity, or osteoporosis). A patient with subclinical Cushing’s syndrome should receive glucocorticoid therapy perioperatively because of the risks of adrenal insufficiency, hemodynamic crisis, and death. The need for longer-term replacement and slow tapering of exogenous glucocorticoids should be assessed postoperatively. In limited case series, weight loss, improvement in hypertension or glycemic control or both, and the normalization of markers of bone turnover were reported after unilateral adrenalectomy in patients with subclinical Cushing’s syndrome.

### Table 1. Symptoms and Signs Suggestive of Adrenal Hyperfunction or Malignant Disease.

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Symptoms</th>
<th>Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cushing’s syndrome</td>
<td>Patient may be asymptomatic if disease is subclinical; symptoms may include weight gain with central obesity, facial rounding and plethora, supraclavicular and dorsocervical fat pads, easy bruising, thin skin, poor wound healing, purple striae, proximal muscle weakness, emotional and cognitive changes (e.g., irritability, spontaneous tearfulness, depression, and restlessness), opportunistic and fungal infections, altered reproductive function, acne, and hirsutism</td>
<td>Hypertension, osteopenia, osteoporosis, fasting hyperglycemia, diabetes mellitus, hypokalemia, hyperlipidemia, and leukocytosis with relative lymphopenia</td>
</tr>
<tr>
<td>Pheochromocytoma</td>
<td>Patient may be asymptomatic; episodic symptoms may occur in spells (paroxysms) that can be extremely variable in presentation but typically include forceful heartbeat, pallor, tremor, headache, and diaphoresis; spells may be either spontaneous or precipitated by postural change, anxiety, medications (e.g., metoclopramide, anesthetic agents), and maneuvers that increase intraabdominal pressure (e.g., change in position, lifting, defection, exercise, colonoscopy, pregnancy, and trauma)</td>
<td>Hypertension (paroxysmal or sustained), orthostatic hypotension, pallor, retinopathy grades 1 to 4, tremor, and fever</td>
</tr>
<tr>
<td>Primary aldosteronism</td>
<td>If hypokalemia is present, nocturia, polyuria, muscle cramps, and palpitations may be present</td>
<td>Hypertension, mild or severe; possibly hypokalemia and mild hypernatremia</td>
</tr>
<tr>
<td>Adrenocortical carcinoma</td>
<td>Symptoms may include mass effect (e.g., abdominal pain) and symptoms related to adrenal hypersecretion of cortisol (Cushing’s syndrome), androgens (hirsutism, acne, amenorrhea or oligomenorrhea, oily skin, and increased libido), estrogens (gynecomastia), or aldosterone (hypokalemia-related symptoms)</td>
<td>Hypertension, osteopenia, osteoporosis, fasting hyperglycemia, diabetes mellitus, hypokalemia, hyperlipidemia, and leukocytosis with relative lymphopenia</td>
</tr>
<tr>
<td>Metastatic cancer</td>
<td>History of an extraadrenal cancer</td>
<td>Cancer-specific signs</td>
</tr>
</tbody>
</table>
Long-term prospective studies are needed to provide a better understanding of the natural history of subclinical Cushing’s syndrome and better guidance for decisions regarding surgical intervention. At least two reports have suggested that cortisol secretion may be normal when the adrenal incidentaloma is discovered but may become autonomous during a subsequent period of 4 years or longer. Until data are available from large prospective studies, these observations suggest that it is reasonable to repeat the hormonal screening annually for 4 years, as suggested by the National Institutes of Health (NIH) state-of-the-science statement.5

**Clinically Silent Pheochromocytoma**

Approximately 5% of adrenal incidentalomas have proved to be pheochromocytomas. In one study, 19 of 33 adrenal pheochromocytomas (58%) were detected initially as incidental adrenal masses, and only 10 of the 19 patients had hypertension. However, even clinically silent pheochromocytomas can be lethal. The characteristics of an adrenal mass on imaging — the imaging phenotype — can be helpful in determining whether it is a pheochromocytoma (Table 3). Findings consistent with (although not diagnostic of) pheochromocytoma include increased attenuation on unenhanced CT, prominent vascularity of the mass (Fig. 2A), delayed washout of contrast medium, and high signal intensity on T2-weighted MRI. Because not all pheochromocytomas have this phenotype and because the expertise of radiologists and clinicians in identifying this rare neoplasm can vary, biochemical assessment is warranted for all patients. Studies reporting the characteristics of biochemical tests for pheochromocytoma are based on data from both symptomatic and asymptomatic patients. The measurement of fractionated metanephrines and

---

**Table 2. Laboratory Evaluation of the Patient with Adrenal Incidentaloma.**

<table>
<thead>
<tr>
<th>Possible Diagnosis</th>
<th>Screening Test</th>
<th>Causes of False Positive Results</th>
<th>Confirmatory Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subclinical Cushing’s syndrome</strong></td>
<td>Overnight dexamethasone (1 mg) suppression test; abnormal result: serum cortisol, &gt;5 μg per deciliter (138 nmol per liter); some clinicians use a higher dose of dexamethasone (e.g., 3 mg instead of the standard 1 mg) to reduce the possibility of a false positive result without a change in sensitivity</td>
<td>Medications that accelerate hepatic metabolism of dexamethasone (e.g., anti-convulsants); noncompliance with dexamethasone regimen</td>
<td>Consider the following tests: serum corticotropin, cortisol in a blood specimen and 24-hr urine specimen, midnight salivary measurement of cortisol, and a formal 2-day high-dose dexamethasone suppression test (the result is considered abnormal when the cortisol level in the 24-hr urine specimen is greater than the lower limit of the normal range for the local laboratory)</td>
</tr>
<tr>
<td><strong>Pheochromocytoma</strong></td>
<td>Measurement of fractionated metanephrines and catecholamines in a 24-hr urinary specimen; imaging phenotype may also suggest pheochromocytoma</td>
<td>Any situation (e.g., illness requiring hospitalization) or medication (e.g., tricyclic antidepressant) that increases endogenous production of catecholamines7</td>
<td>Consider iodine-123 metaiodobenzylguanidine scintigraphy, MRI, subspecialty consultation, and surgery</td>
</tr>
<tr>
<td><strong>Primary aldosteronism</strong></td>
<td>Morning measurement of the plasma aldosterone concentration and plasma renin activity,8 which can be performed while the patient is receiving any antihypertensive drug except spironolactone (Aldactone, Searle), eplerenone (Inspra, Pfizer), or high-dose amiloride (Midamor, Merck); the plasma aldosterone concentration and plasma renin activity ratio of ≥20 and a plasma aldosterone concentration of ≥15 ng per deciliter are positive results (but the cutoff for a positive result is laboratory-dependent)</td>
<td>Assay and biologic variability</td>
<td>To confirm the diagnosis of primary aldosteronism: aldosterone suppression testing with either a saline infusion test or 24-hour urinary aldosterone excretion test while the patient maintains a high-sodium diet8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>To confirm that the adrenal mass (and not bilateral adrenal hyperplasia) is the source of aldosterone excess in patients with documented primary aldosteronism, adrenal venous sampling should be considered8</td>
</tr>
</tbody>
</table>

* In this test, values for the plasma aldosterone concentration are in nanograms per deciliter, and values for plasma renin activity are in nanograms per milliliter per hour.
catecholamines in a 24-hour urine specimen is recommended for all patients with adrenal incidentalomas; the detection of elevated levels of fractionated metanephrines, catecholamines, or both has high sensitivity and specificity for pheochromocytoma (91 to 98% in Mayo Clinic series, for both). The additional measurement of fractionated catecholamines in the 24-hour urinary specimen increases the sensitivity of this approach by 5% and is especially helpful in diagnosing patients with dopamine-secreting neoplasms. If the suspicion of subclinical pheochromocytoma is high on the basis of the imaging phenotype but the results of 24-hour urinary studies are normal, the measurement of fractionated plasma free metanephrines (available at most reference laboratories) may be useful. Although elevated levels of fractionated plasma metanephrines have high sensitivity for pheochromocytoma (96 to 100%), the test has low specificity (85 to 89% overall and 77% in patients older than 60 years). Thus, the measurement of fractionated plasma metanephrines is recommended only when suspicion is high, to minimize the risk of false positive results that might lead to unnecessary surgery.

**Primary Aldosteronism**

Approximately 1% of adrenal incidentalomas have proved to be aldosterone-producing adenomas. Excessive secretion of aldosterone is associated with an increased risk of cardiovascular disease.
and other disorders,7 and the normalization of circulating aldosterone levels or mineralocorticoid receptor blockade is warranted in patients with excessive secretion of aldosterone.8 Screening for hyperaldosteronism is routinely recommended for hypertensive patients who have an adrenal incidentaloma. Given that patients with aldosterone-producing adenomas may have normal levels of potassium in the blood,30 the measurement of potassium levels is not reliable in screening. A reasonable screening test is the ratio of the ambulatory morning plasma aldosterone concentration to plasma renin activity (Table 2).30,31 If this ratio is high, the diagnosis of primary aldosteronism should be confirmed by an additional measurement of mineralocorticoid secretory autonomy (Table 2).8

Other Hormonally Active Processes
Sex hormone–secreting adrenocortical tumors are rare and typically occur in the presence of clinical manifestations (e.g., hirsutism or virilization).1 Routine screening for excess androgens or estrogens in patients with adrenal incidentalomas is therefore not warranted.

Nonclassic congenital adrenal hyperplasia is another infrequent cause of adrenal incidentalomas (unilateral or bilateral).1 Cosyntropin-stimulation testing with the measurement of cortisol precursors (e.g., 17-hydroxyprogesterone) is not routinely recommended but, rather, should be reserved for patients in whom the diagnosis is suspected on the basis of clinical manifestations (e.g., hyperandrogenism) or the presence of bilateral adrenal masses.

ASSESSMENT OF MALIGNANT POTENTIAL
The possibility of malignant disease is the major concern when an incidental adrenal mass is identified. Among 2005 patients in whom adrenal incidentalomas were detected, adrenocortical carcinoma was found in 4.7% of the patients and

---

Table 3. Characteristics of Adrenal Incidentalomas on Imaging (Imaging Phenotype).a

<table>
<thead>
<tr>
<th>Variable</th>
<th>Adrenocortical Adenoma</th>
<th>Adrenocortical Carcinoma</th>
<th>Pheochromocytoma</th>
<th>Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size</td>
<td>Small, usually ≤3 cm in diameter</td>
<td>Large, usually &gt;4 cm in diameter</td>
<td>Large, usually &gt;3 cm in diameter</td>
<td>Variable, frequently &lt;3 cm</td>
</tr>
<tr>
<td>Shape</td>
<td>Round or oval, with smooth margins</td>
<td>Irregular, with unclear margins</td>
<td>Round or oval, with clear margins</td>
<td>Oval or irregular, with unclear margins</td>
</tr>
<tr>
<td>Texture</td>
<td>Homogeneous</td>
<td>Heterogeneous, with mixed densities</td>
<td>Heterogeneous, with cystic areas</td>
<td>Heterogeneous, with mixed densities</td>
</tr>
<tr>
<td>Laterality</td>
<td>Usually solitary, unilateral</td>
<td>Usually solitary, unilateral</td>
<td>Usually solitary, unilateral</td>
<td>Often bilateral</td>
</tr>
<tr>
<td>Attenuation (density) on unenhanced CT</td>
<td>≤10 Hounsfield units (usually &gt;25)</td>
<td>&gt;10 Hounsfield units (usually &gt;25)</td>
<td>&gt;10 Hounsfield units (usually &gt;25)</td>
<td>&gt;10 Hounsfield units (usually &gt;25)</td>
</tr>
<tr>
<td>Vascularity on contrast-enhanced CT</td>
<td>Not highly vascular</td>
<td>Usually vascular</td>
<td>Usually vascular</td>
<td>Usually vascular</td>
</tr>
<tr>
<td>Rapidity of washout of contrast medium</td>
<td>≥50% at 10 minutes</td>
<td>&lt;50% at 10 minutes</td>
<td>&lt;50% at 10 minutes</td>
<td>&lt;50% at 10 minutes</td>
</tr>
<tr>
<td>Appearance on MRI†</td>
<td>Isointense in relation to liver on T2-weighted image</td>
<td>Hyperintense in relation to liver on T2-weighted image</td>
<td>Markedly hyperintense in relation to liver on T2-weighted image</td>
<td>Hyperintense in relation to liver on T2-weighted image</td>
</tr>
<tr>
<td>Necrosis, hemorrhage, or calcifications</td>
<td>Rare</td>
<td>Common</td>
<td>Hemorrhage and cystic areas common</td>
<td>Occasional hemorrhage and cystic areas</td>
</tr>
<tr>
<td>Growth rate</td>
<td>Usually stable over time or very slow (&lt;1 cm per year)</td>
<td>Usually rapid (&gt;2 cm per year)</td>
<td>Usually slow (0.5 cm to 1.0 cm per year)</td>
<td>Variable, slow to rapid</td>
</tr>
</tbody>
</table>

a Adrenal hemorrhage and myelolipoma are usually easily characterized because of their distinctive imaging characteristics.24,25 Myelolipomas are composed of myeloid, erythroid, and adipose tissue. On imaging, they have low attenuation on unenhanced CT, and they are hyperintense on T1-weighted in-phase MRI. The presence of pure fat within an adrenal lesion on CT is consistent with the presence of a myelolipoma. Acute adrenal hemorrhage has increased attenuation on unenhanced CT, and on T1-weighted MRI, there is hyperintensity secondary to methemoglobin. In a chronic adrenal hemorrhage, a dark rim develops along the periphery of the mass on the T2-weighted image because of the hemosiderin-laden macrophages.

† If the imaging characteristics are indeterminate on both unenhanced and enhanced CT, MRI may be considered to clarify the imaging phenotype.
metastatic cancer in 2.5%. The size of the mass and its appearance on imaging are the two major predictors of malignant disease.

Size of Adrenal Mass
In a report involving 887 patients who had adrenal incidentalomas, a diameter greater than 4 cm was shown to have 90% sensitivity for the detection of adrenocortical carcinoma but low specificity; only 24% of lesions greater than 4 cm in diameter were malignant. Size is also important because the smaller an adrenocortical carcinoma is at the time of diagnosis, the lower the tumor stage is and the better the overall prognosis will be. Although most experts would recommend resection of adrenal masses larger than 6 cm in diameter, decisions regarding surgery should also take into account the imaging phenotype of the mass, as well as the patient’s age and any coexisting conditions. For example, a nonfunctioning adrenal incidentaloma that is 6.5 cm in diameter and has a benign imaging phenotype may be reasonably followed in an octogenarian. Because the prevalence of benign adrenal cortical adenomas increases with age, the finding of a nonfunctioning adrenal mass that is 3.2 cm in diameter in a younger patient (e.g., below the age of 30 years) should increase the suspicion of an alternative diagnosis. The size of an adrenal incidentaloma does not affect recommendations regarding biochemical testing.

Imaging Phenotype
The CT features used to distinguish adenomas from nonadenomas are the lipid content of the
adrenal mass and rapidity of the washout of contrast medium (Table 3). The intracytoplasmatic fat in adenomas results in low attenuation on unenhanced CT (Fig. 2B); nonadenomas have higher attenuation on unenhanced CT. On chemical-shift MRI (a form of lipid-sensitive imaging that is routinely used), benign adrenocortical adenomas lose signal on out-of-phase images, as compared with in-phase images. However, up to 30% of adenomas do not contain large amounts of lipid and may be indistinguishable from nonadenomas on both unenhanced CT and chemical-shift MRI.

On delayed contrast-enhanced CT, adenomas typically exhibit rapid washout of contrast medium, whereas other adrenal nonadenomas have delayed washout of contrast material (Table 3). Ten minutes after the administration of the contrast medium, an absolute washout of more than 50% of the contrast medium was reported to be 100% sensitive and specific for adenoma in a comparison between patients with adenomas and those with carcinomas, pheochromocytomas, or metastatic disease. Although the imaging phenotype does not predict hormonal function, it does predict the underlying pathology, and surgical resection should be considered for patients who have adrenal incidentalomas with a suspicious imaging phenotype (Fig. 2C).

**Metastatic Disease**

Metastases are the cause of the adrenal incidentaloma in approximately half of patients who have a history of malignant disease. Tumors that commonly metastasize to the adrenals include carcinomas of the lung, kidney, colon, breast, esophagus, pancreas, liver, and stomach (Fig. 3A and 3B). Metastases to the adrenal glands are frequently bilateral. The primary cancer usually has already been recognized when an adrenal incidentaloma is discovered; metastatic cancer to the adrenal without a known primary cancer is extremely rare.

Positron-emission tomography (PET) with $^{18}$F-fluorodeoxyglucose ($^{18}$F-FDG) can be helpful in selected patients (those with a history of malignant disease) because of its high sensitivity in detecting malignant diseases. However, 16% of benign adrenal lesions may have greater FDG-PET uptake than the background uptake. The absence of activity on $^{13}$C-metomidate (MTO)–PET appears to be specific for tumors of nonadrenocortical origin (e.g., pheochromocytomas and metastatic disease), but this type of imaging is not routinely available. Because of their cost and because there are insufficient data to support their routine use, FDG-PET and MTO-PET are not recommended for the evaluation of a patient with an adrenal incidentaloma who does not have a history of malignant disease.

**Fine-Needle Aspiration Biopsy**

The primary role of fine-needle aspiration biopsy is to differentiate between adrenal tissue and nonadrenal tissues (e.g., metastases or infection). Image-guided fine-needle aspiration biopsy is relatively safe; the complication rate was 2.8% in one series of 277 biopsies. The risks of this procedure include adrenal hematoma, abdominal pain, hematuria, pancreatitis, pneumothorax, formation of an adrenal abscess, and tumor recurrence along the needle track. Also, fine-needle aspiration biopsy of a pheochromocytoma may result in hemorrhage and hypertensive crisis, and the possibility of pheochromocytoma should always be ruled out by biochemical testing before fine-needle aspiration biopsy is undertaken.

**Bilateral Adrenal Masses**

When adrenal masses occur bilaterally (as they do in up to 15% of patients with adrenal incidentaloma), the most likely diagnoses are metastatic disease, congenital adrenal hyperplasia, bilateral cortical adenomas, and infiltrative disease of the adrenal glands. Adrenocortical hypofunction may occur in patients with bilateral adrenal masses, so screening for adrenocortical hypofunction may be prudent in such patients, although the yield is unknown.

### Areas of Uncertainty

The optimal frequency and duration of follow-up for patients who have adrenal incidentalomas are uncertain, and prospective data to guide the clinician are scarce. Repeated imaging is commonly recommended at 6, 12, and 24 months; earlier follow-up (at 3 months) has been suggested when the imaging phenotype is suspicious (Fig. 1), with the rationale that many malignant lesions will grow during this 3-month interval (Fig. 3A and 3B), resulting in earlier intervention. However, the yield and cost-effectiveness of repeated imaging at these intervals are uncertain. On the basis of our
unpublished experience with nine patients who underwent serial imaging, the typical rate of growth of benign adrenal pheochromocytoma is approximately 0.5 to 1.0 cm in diameter per year (Fig. 3C through 3F), whereas adrenocortical carcinomas typically have a rapid growth rate (>2 cm per year) (Fig. 3G and 3H). However, most adrenal masses that grow are not malignant. In case series of adrenal incidentalomas followed for an average of 4 years, 5 to 20% increased in size, and 1.3 to 5.2% decreased in size.1,21,48 In two of these series, only 1 of 9 patients and none of 11 patients with enlarging adrenal masses who underwent surgery were found to have malignant tumors.21,48 Less frequent imaging during follow-up is reasonable for patients who have no history of malignant disease and who have small (<2 cm), uniform, hypodense cortical nodules.

The observation that abnormal adrenal function (secretion of glucocorticoids and catecholamines) that is not present at baseline may be detected during follow-up testing21,48,49 has led to the recommendation of repeating hormonal evaluation annually for at least 4 years when the initial evaluation is negative.5,48,49 However, the yield and cost-effectiveness of such testing are unknown.

**Figure 3. Serial CT Scans Showing Metastatic Disease to the Adrenal Gland (Panels A and B), a Benign Pheochromocytoma (Panels C through F), and Adrenocortical Carcinoma (Panels G and H).**

On abdominal CT in a 63-year-old man with a history of colon cancer, a mass, 1.0 cm in diameter, was found in the left adrenal gland (Panel A, arrow); an image obtained 3 months later shows marked growth of the mass (3 cm in diameter) (Panel B, arrow). After biochemical testing had ruled out pheochromocytoma, a diagnosis of metastatic colon cancer was confirmed on CT-guided fine-needle aspiration biopsy. On initial CT performed to evaluate nephrolithiasis in a 66-year-old man, a right adrenal mass, 1.7 cm by 1.3 cm (Panel C, arrow), was incidentally discovered. Two years later (after prostate cancer had been diagnosed), CT revealed that the right adrenal mass had enlarged (2.6 cm by 2.4 cm) (Panel D, arrow). Repeated CT after an additional 2 years of follow-up showed further growth of the mass (3.2 cm by 2.9 cm) (Panel E, arrow); another follow-up scan obtained 1 year later (i.e., 5 years after the mass was initially noted) showed further enlargement of the mass (3.8 cm by 3.3 cm) (Panel F, arrow). The patient did not have symptoms of pheochromocytoma. He had long-standing hypertension that was treated with a single antihypertensive agent until 2001, when poor blood-pressure control required the addition of two more antihypertensive agents. In 2002, diabetes mellitus developed. Although his urine and plasma normetanephrine levels had not been checked previously, on testing in July 2005, they were found to be markedly elevated. The patient was treated with α- and β-adrenergic blockade, followed by laparoscopic adrenalectomy; the pathological examination confirmed the diagnosis of pheochromocytoma. At follow-up 1 year after surgery, the diabetes mellitus had resolved and the hypertension was well controlled with one agent. On abdominal CT in a 69-year-old woman with pulmonary symptoms, a slightly thickened right adrenal gland was found (Panel G, arrow). Two years later, an image obtained to evaluate right upper quadrant abdominal pain showed a right adrenal mass, 8.0 cm by 6.5 cm by 6.0 cm (Panel H, arrow). The results of biochemical testing were normal. The patient underwent an open procedure for resection of a nonfunctional adrenocortical carcinoma.
ommendations given here are in general agreement with the NIH state-of-the-science statement on adrenal incidentalomas, which was published in 2003.5

CONCLUSIONS AND RECOMMENDATIONS

For the patient described in the vignette, a thorough history should be obtained and a physical examination performed to assess the evidence of adrenal hormone excess (Table 1). I would perform a 1-mg overnight dexamethasone suppression test, collect a 24-hour urinary specimen for measurement of fractionated metanephrines and catecholamines, and (because she has hypertension) measure the plasma aldosterone concentration and plasma renin activity. If the results of the initial hormonal testing are consistent with autonomous hormone secretion, and if this finding is confirmed by subsequent studies, unilateral laparoscopic adrenalectomy should be considered.

The adrenal imaging should be reviewed with a radiologist. If the imaging phenotype suggests infection or metastatic disease, CT-guided fine-needle aspiration biopsy should be considered (after biochemical testing to rule out pheochromocytoma). If the results of hormonal testing are normal and the imaging features are consistent with benign disease, I would recommend repeating the imaging studies at 6, 12, and 24 months and repeating the hormonal evaluation yearly for 4 years, even though there are no data from large, long-term studies to support these recommendations. Although the data are also scarce to suggest when surgery is necessary, I would recommend consideration of adrenalectomy if the adrenal mass is 4 cm or greater in diameter, if the mass enlarges by 1 cm or more during the period of observation, or if evidence of autonomous hormonal secretion develops.

No potential conflict of interest relevant to this article was reported.

REFERENCES


Copyright © 2007 Massachusetts Medical Society.